Skip to main content
Premium Trial:

Request an Annual Quote

Pairings: Jul 14, 2010


Myriad Genetics announced last week the appointment of Gary King to the newly created position of executive vice president of international operations. King will oversee Myriad's expansion into Europe and other international markets. His immediate focus will be commercializing Myriad's eight diagnostic products in major market countries of Germany, France, Italy, Spain, and the United Kingdom, the company said.

Prior to joining Myriad, King was CEO of the international biotech firm AverDx. King also served as the VP of international operations at Biosite and as division director in Japan for Guidant.

The Scan

Harvard Team Report One-Time Base Editing Treatment for Motor Neuron Disease in Mice

A base-editing approach restored SMN levels and improved motor function in a mouse model of spinal muscular atrophy, a new Science paper reports.

International Team Examines History of North American Horses

Genetic and other analyses presented in Science find that horses spread to the northern Rockies and Great Plains by the first half of the 17th century.

New Study Examines Genetic Dominance Within UK Biobank

Researchers analyze instances of genetic dominance within UK Biobank data, as they report in Science.

Cell Signaling Pathway Identified as Metastasis Suppressor

A new study in Nature homes in on the STING pathway as a suppressor of metastasis in a mouse model of lung cancer.